

To: 5.1.2e | 5.1.2e @efpia.eu]
Cc: 5.1.2e | 5.1.2e @efpia.eu]; 5.1.2e | 5.1.2e @cefic.be];
 5.1.2e @nl.aspenpharma.com | 5.1.2e @nl.aspenpharma.com]; restrictiePFAS | 5.1.2i @rivm.nl]
From: 5.1.2e
Sent: Thur 4/13/2023 8:18:43 AM
Subject: RE: EFPIA & EFCG Outreach - PFAS Restriction
Received: Thur 4/13/2023 8:18:44 AM

Hi 5.1.2e

Thank you for these dates. I'll check those with my colleagues and get back to you a.s.a.p.

Best regards,

5.1.2e

From: 5.1.2e <5.1.2e @efpia.eu>

Sent: donderdag 13 april 2023 10:10

To: 5.1.2e <5.1.2e @rivm.nl>

Cc: 5.1.2e <5.1.2e @efpia.eu>; 5.1.2e <5.1.2e @cefic.be>; 5.1.2e @nl.aspenpharma.com; restrictiePFAS
 <5.1.2i @rivm.nl>

Subject: Re: EFPIA & EFCG Outreach - PFAS Restriction

Dear 5.1.2e,

I apologise I omitted some possibilities for the online meeting on the PFAS restriction. In order of preference, here are the possibilities from our end:

- Tuesday 25 April (am or pm)
- Wednesday 26 April (morning only)
- Thursday 20 April (am or pm)
- Friday 21 April (am or pm)

Please let us know if there are any specific discussion points you would like addressed during the call.

Happy to assist further with the scheduling of the call.

Kind regards,

5.1.2e

On Wed, 12 Apr 2023 at 16:10, 5.1.2e <5.1.2e @efpia.eu> wrote:

Dear 5.1.2e

Thanks for agreeing to discuss our PFAS applications, would the following dates work for you and your colleagues:

- Thursday 20 April (am or pm)
- Friday 21 April (am or pm)

Please let us know if there are any specific discussion points you would like addressed during the call.

Happy to assist further with the scheduling of the call.

Kind regards,

5.1.2e

On Wed, 12 Apr 2023 at 09:38, 5.1.2e <5.1.2e @rivm.nl> wrote:

Dear 5.1.2e

I think an online meeting would be useful to exchange some information and questions and answers with each other, especially since your organisations represent quite a large number of users of PFASs for specific applications. And since we are looking for information on sector level rather than only on company level, your input in the consultation would be highly appreciated.

An online meeting would be best, as there is also interest from colleagues from Norway and possibly Sweden to attend the meeting. From our side, I'll try and see if the people that have specific knowledge on the SEA part and on pharmaceuticals and medical devices can attend.

Which dates/times would suit you best? Then I can go back to my colleagues with these suggestions for a meeting date and time.

Met vriendelijke groet / Kind regards,

5.1.2e

5.1.2e

Centrum voor Veiligheid van Stoffen en Producten | Centre for Safety of Substances and Products
 Rijksinstituut voor Volksgezondheid en Milieu | National Institute for Public Health and the Environment

Bezoekadres / Visitors: Antonie van Leeuwenhoeklaan 9 | 3721 MA Bilthoven | The Netherlands

Postadres / Correspondence: Postbus 1 | 3720 BA Bilthoven | The Netherlands

T: 5.1.2e | **M:** 5.1.2e

E: 5.1.2e @rivm.nl | **W:** www.rivm.nl/en



Out of office on Fridays - Niet op kantoor op vrijdagen

From: 5.1.2e <5.1.2e@efpia.eu>

Sent: woensdag 5 april 2023 15:09

To: 5.1.2e <5.1.2e@rivm.nl>

Cc: 5.1.2e <5.1.2e@efpia.eu>; 5.1.2e <1.2@cefic.be>; 5.1.2e @nl.aspenpharma.com

Subject: EFPIA & EFCG Outreach - PFAS Restriction

Dear 5.1.2e,

EFPIA (European Federation of Pharmaceutical Industries Association) and EFCG (European Fine Chemicals Group) will be contributing to the public consultation on the PFAS Restriction. The aforementioned trade associations represent the actors of the pharmaceutical supply chain, who are responsible for the development, manufacture, and supply of medicinal products in the EU.

Earlier today at the ECHA webinar, reference was made to a guidance note on information to be submitted during the public consultation. The guidance indicates that insufficient detail on several PFAS uses including medicinal products has been provided and information on socio-economic impact is requested. To help the ECHA Committees, we would like clarification on the financial and patient impact information that should be provided during the public consultation. Also, during a CEFIC workshop, on Thursday 30 March, when we discussed the socio-economic information requirements with 5.1.2e, it was recommended that we speak with you.

As recommended at the ECHA webinar we would like to submit appropriate information as early as possible. We are amenable to a face-to-face meeting in Bilthoven, or to speak over a video call, at your earliest convenience. It is recognised that this is a very busy time for you, and we greatly appreciate any consideration given to this request. Thank you for your time and kind consideration and we very much look forward to hearing from you.

Kind regards,

--

5.1.2e

European Federation of Pharmaceutical Industries and Associations

Leopold Plaza Building

Rue du Trône 108

B-1050 Brussels (Belgium)

Tel: 5.1.2e (mobile)

Email: 5.1.2e @efpia.eu

www.efpia.eu

Dit bericht kan informatie bevatten die niet voor u is bestemd. Indien u niet de geadresseerde bent of dit bericht abusievelijk aan u is verzonden, wordt u verzocht dat aan de afzender te melden en het bericht te verwijderen. Het RIVM aanvaardt geen aansprakelijkheid voor schade, van welke aard ook, die verband houdt met risico's verbonden aan het elektronisch verzenden van berichten.

www.rivm.nl De zorg voor morgen begint vandaag

This message may contain information that is not intended for you. If you are not the addressee or if this message was sent to you by mistake, you are requested to inform the sender and delete the message. RIVM accepts no liability for damage of any kind resulting from the risks inherent in the electronic transmission of messages.

www.rivm.nl/en Committed to health and sustainability